STOCK TITAN

NuCana (NASDAQ: NCNA) CEO Hugh S. Griffith returns from health leave

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

NuCana plc reports that Hugh S. Griffith has returned to his role as Chief Executive Officer and principal executive officer, effective December 15, 2025.

During his health-related leave, Executive Chairman Andrew Kay had been acting as the company’s principal executive officer; upon Mr. Griffith’s return, Mr. Kay resumed his prior position as Chairman of the Board. The update is also stated to be incorporated by reference into NuCana’s existing shelf and equity compensation registration statements on Form F-3 and Form S-8.

Positive

  • None.

Negative

  • None.
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025

(Commission File No. 001-38215)

 

 

NUCANA PLC

(Translation of registrant’s name into English)

 

 

3 Lochside Way

Edinburgh EH12 9DT

United Kingdom

(Address of registrant’s principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7): ☐

 

 
 


Corporate Update

Effective December 15, 2025, Hugh S. Griffith returned to his role as Chief Executive Officer of NuCana plc (the “Company”) and resumed his position as the Company’s principal executive officer. Upon Mr. Griffith’s return, Andrew Kay, who had been serving as Executive Chairman of the Company’s Board of Directors (the “Board”) and acting as the Company’s principal executive officer during Mr. Griffith’s leave, returned to his prior role as Chairman of the Board.

As previously disclosed in June 2025, Mr. Griffith had taken a leave of absence due to health reasons.

The information in this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3, as amended (File Number 333-281576) and Form S-8 (File Number 333-223476 and File Number 333-248135), and related prospectuses, as such registration statements and prospectuses may be amended from time to time, and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

NuCana plc

By:  

/s/ Ian Webster

Name:   Ian Webster
Title:   Interim Chief Financial Officer (Principal Financial and Accounting Officer)

Date: December 17, 2025

FAQ

What leadership change did NuCana plc (NCNA) disclose in this report?

NuCana disclosed that Hugh S. Griffith has returned to his role as Chief Executive Officer and principal executive officer. He had previously been on a health-related leave of absence.

When did Hugh S. Griffith resume his role as NuCana CEO?

The report states that Hugh S. Griffith resumed his role as Chief Executive Officer and principal executive officer of NuCana plc effective December 15, 2025.

What is Andrew Kay’s position at NuCana after this change?

After Hugh S. Griffith’s return, Andrew Kay moved from serving as Executive Chairman and acting principal executive officer back to his prior role as Chairman of the Board.

Why had Hugh S. Griffith taken a leave of absence from NuCana?

The report notes that, as previously disclosed in June 2025, Hugh S. Griffith took a leave of absence from NuCana for health reasons.

How is this corporate update used in NuCana’s SEC registration statements?

The corporate update is stated to be incorporated by reference into NuCana’s registration statements on Form F-3 (File No. 333-281576) and Form S-8 (File Nos. 333-223476 and 333-248135), becoming part of those documents from the date this report is filed.

Nucana

NASDAQ:NCNA

NCNA Rankings

NCNA Latest News

NCNA Latest SEC Filings

NCNA Stock Data

14.44M
7.17M
0%
0.24%
18.77%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
GAITHERSBURG